Once-weekly injectable insulin products are similarly set to transform type 2 diabetes management, with evidence of greater improvement in long-term glucose control and time within normal range across seven randomised clinical trials (n = 3286, 60% on once-weekly injectable insulin) (6). The gene discussed is INS; the disease is type 2 diabetes mellitus.